United Therapeutics, Liquidia settle Yutrepia patent litigation, agree to dismiss cases with prejudice
United Therapeutics reached a settlement with Liquidia to end multiple patent disputes tied to Yutrepia sales and labeling. Liquidia must pay USD 185 million within 30 business days for past PH-ILD sales from June 2, 2025 through execution. Liquidia also agreed to pay USD 145.4 million in two installments due by Jan. 3